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Abstract 
Deep-Brain Stimulation (DBS) is a therapy used in conjunction with medication to help alleviate the motor symptoms of 
Parkinson’s Disease (PD). However, the monitoring and adjustment of DBS settings is tedious and expensive, requiring long 
programming appointments every few months. We investigated the possible correlation between PD motor score severity and 
digitally extracted patient voice features to potentially aid clinicians in their monitoring and treatment of PD with DBS to 
eventually enable a closed-loop DBS system. 5 DBS PD patients (4 bilateral STN, 1 bilateral GPI) were enrolled. Voice 
samples were collected for various voice tasks (single phoneme vocalization, free speech task, sentence reading task, 
counting backward task, categorical fluency task) for DBS in ON and OFF states. Motor scores per the Unified Parkinson’s 
Disease Rating Scale (UPDRS) were also collected for DBS ON and OFF states.  Voice samples were then analyzed to 
extract voice features using publicly available voice feature library sets, and statistically compared for DBS ON and OFF. Of 
the feature categories explored (Acoustic, Prosodic, Linguistic) 6 features from the GeMAPS feature set for acoustic features 
demonstrated significant differences with DBS ON and OFF (p < 0.05). Prosodic features such as pause length/percentage 
were found to be negatively correlated with increased motor symptom severity. Non-significant differences were found for 
linguistic features. These findings provide preliminary evidence for acoustic and prosodic speech features to act as potential 
biomarkers for PD disease severity in DBS patients. We hope to explore further by expanding our data set, identifying other 
features and applying potential machine learning models, working towards a closed-loop DBS system that can auto-tune itself 
based on changes in a patient’s voice.  
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1. Introduction: 
1.1 Parkinson’s and Deep-Brain Stimulation: 
    Parkinson’s Disease (PD) is the second most common 
neurodegenerative disease, expected to affect 930,000 
patients in the US by 2020, projecting to over 1.3 million 
people by 2030 [1]. Known for its motor symptoms of 
muscle rigidity, bradykinesia and tremor, PD also effects the 
fundamental frequency , jitter, and harshness of voice [2]. 
Along with medication, PD can be treated using Deep-Brain 
Stimulation (DBS), where an electrode is surgically 
implanted into the brain, delivering electric current to 
alleviate symptoms. Specific targets for DBS include the 
sub-thalamic nuclei (STN) or globus pallidus internus (GPI) 
in the indirect pathway of the basal ganglia thalamocortical 
circuit, the pathway contributing to the inhibition of 
movements associated with PD pathology [3]. The best DBS  
candidates for PD include patients with significant responses 
to levodopa, and lack of comorbidities, particularly cognitive 
and surgically related [4].  An estimated 150,000 patients 
with movement disorders (PD, essential tremor, etc.) have 
been treated with DBS in the United States [5]. 
1.2 Voice Biomarker Closed-Loop DBS: 
    DBS treatment is an arduous and expensive process. 
Patients must come in every few months to have their DBS 
settings carefully adjusted with the progressions of their 
symptoms. While modern DBS devices have wireless 
charging capabilities, older devices must have their batteries 
surgically replaced every few years. Closed-loop DBS refers 
to a system which makes adjustment to the DBS signal 
without the need for manual adjustment. This could reduce 
the need for patients to come into clinic, and prolong the 
battery life of the function generators on their DBS devices. 
Closed-loop DBS has been explored using physiological 
feedback loops, particularly with motor cortex 
electrocorticography (ECoG), electroencephalography 
(EEG), and wearable wrist accelerometer as physiological 
sensors [6]&[7]. Previously, our lab has identified methods 
to utilize digital biomarkers extracted from voice samples, to 
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build models that can predict presence of PD [8]. Other work 
has shown changes in vocal motor mechanisms of PD with 
DBS ON and OFF [9], and changes in the quality, intensity 
and prosody of patient voice for PD amongst different DBS 
settings [10]. We aim to identify objective and quantifiable 
voice features that correlate with DBS turned ON and OFF in 
PD patients, that we could potentially apply to use as 
feedback for closed-loop system DBS.  
 
Figure 1: Proposed Closed-Loop DBS System 
2. Materials and Methods: 
2.1 Data Collection: 
Selection criteria for this study were any patients who 
underwent DBS treatment for PD at the University of 
Washington Medical Center.  5 DBS PD patients were 
enrolled in this study (3 male, 2 female). Patient demographics 
are displayed on Table 1. 4 of the patients underwent bilateral 
STN targeted DBS, and 1 patient underwent bilateral GPI 
targeted DBS (patient 5*). Levodopa Equivalency Dosage 
(LED) was calculated per Tomlinson et al. [11], and is used to 
normalize patient dosages to a Levodopa equivalent. 
2.2 Motor Scores: 
Motor scores per the Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale Part III (UPDRS) [12] were 
collected for each patient for DBS in the ON and OFF states 
by a trained movement disorders neurologist.  The UPDRS 
part III is a rating tool used to determine the severity of motor 
symptoms (e.g. muscle rigidity, posture, finger tapping, 
tremor etc.) Each item is rated on a scale of 0-4, with 4 being 
the most severe. The UPDRS Part III has a total of 33 items 
for a total score range of 0-132. Scores recorded were used to 
demonstrate the change in PD motor symptom severity for 
DBS ON and OFF. 
2.3 Voice Tasks: 
Voice recordings were collected using smartphone 
microphone, located an arm’s length away from the mouth. 5 
distinct voice tasks for DBS ON and OFF were collected, for 
a total of 10 voice recordings for each patient. These voice 
tasks included 10 seconds of single phoneme sound, /ˈɑ/, 
pronounced “ahhh”, 30 second free speech task, standardized 
sentence reading task, counting backwards task, and a 30 
second categorical fluency task – having participants name as 
many animals as they could in the allotted time. Transcripts 
for free speech and categorical fluency tasks were also 
generated for text analysis.  
2.4 Feature Extraction: 
Voice samples were extracted for features using publicly 
available feature extraction pipelines [13] and [14]. Acoustic 
features extracted were derived from the Geneva Minimalistic 
Acoustic Parameter Set (GeMAPS), consisting of 88 acoustic 
voice features, such as fundamental frequency, jitter, 
shimmer, etc. [15]. The second feature set extracted was for 
prosody features, which included 7 features looking at 
speech/pause characteristics [16]. Patient free speech tasks 
were used to extract Linguistic Features of Complexity set, 
including 7 features identifying lexical richness [16], and 
Natural Language Toolkit (NLTK) set, including 37 features 
identifying linguistic repeats, consonant, and vowel use [17]. 
2.5 Data Analysis: 
To identify significant changes for DBS ON compared to 
off, paired T-tests were performed on all extracted features. 
Pearson correlation coefficients were generated to identify 
correlation between prosody features and motor symptom 
severity.
 
Patient ID Age/Sex PD Duration 
(Year) 
Time from DBS 
Surgery  
(Year) 
UPDRS-III 
Scores 
OFF/ON 
Levodopa 
Equivalent  
Dosage 
1 86/F 5 0.83 36/30 75 
2 69/M 15 0.83 23/15 2000 
3 71/F 6  0.83 27/21 800 
4 52/M 16 0.83 45/24 1740 
5* 68/M 12 2.5 51/40 1950 
Table 1: Patient Demographics
3. Results: 
3.1 GeMAPS Features: 
Table 2 displays our results for GeMAPS features. For α = 
0.05, we identified 6 significant features. Since we only 
collected recordings from five patients, we thought that our 
small dataset could hinder significant features. As such, Table 
2 also includes features that were below a cutoff threshold of 
p = 0.1, leading to 11 total features presented of the 88 total 
GeMAPS features. 
 
 GeMAPS 
Feature ID 
DBS OFF 
(Mean ± SD) 
DBS ON 
(Mean ± SD) 
p 𝐹" Semitone 
Rising Slope 
Mean 
330.8 ± 208.8 223.2 ± 151.9 0.002* 
𝐹" Semitone 
20th 
Percentile 
26.6 ± 5.6 25.6 ± 6.3 0.078 
𝐹" Semitone 
Rising Slope 
Variance 
470.2 ± 297.2 277.1 ± 270.7 0.002* 
𝐹# 
Bandwidth 
Mean 
830.3 ± 97.6 867.9 ± 112.9 0.018* 
Mean 
Unvoiced 
Segment 
Length  
0.25 ± 0.19 0.30 ± 0.24 0.059 
Alpha Ratio 
Mean  
-7.11 ± 13.5 -9.37 ± 13.0 0.062 
Hammarberg 
Index 
Variance 
0.678 ± 0.575 0.550 ± 0.365 0.065 
Loudness 
Peaks per 
Second 
2.52 ± 1.13 2.11 ± 0.99 0.005* 
 
Loudness 
Mean 
Falling 
Slope 
5.35 ± 3.13 4.40 ± 2.07 0.044* 
Loudness 
Variance 
0.74 ± 0.23 0.81 ± 0.31 0.011* 
Spectral 
Slope 500-
1500 Hz 
mean 
0.0056 ± 
0.0079 
0.0038 ± 
0.0076 
0.051 
Table 2: GeMAPS Features Extracted with p < 0.1 
3.2 Prosodic Features: 
No statistically significant differences were found for 
prosody features, thus we decided to look at the correlation 
between motor symptom severity via the UPDRS part III 
scores and the different prosodic features. Correlation 
coefficients between prosody features and motor scores are 
displayed on Figure 2. Many prosody features significantly 
correlated with other prosody features. This confirmed our 
assumption that many of the prosody features were related, i.e. 
pause length was strongly correlated with pause percentage. 
Pause percentage, demonstrated the largest correlation with 
motor scores, with a correlation coefficient of -0.6. All other 
prosody features were also negatively correlated with motor 
symptom severity.  
 
 
Figure 2: Heatmap for Prosodic Features 
3.3 Linguistic Features: 
Table 3 displays our results for various linguistic features. 
From the NLTK set we looked at the number of repeats in a 
task. From Linguistic Features of Complexity, we looked at 
Brunet’s index, Honore’s statistic, and the type-token ratio 
[16]. Differences between these features for DBS ON and OFF 
were insignificant.  
 
Linguistic 
Feature ID 
DBS OFF 
(Mean ± SD) 
DBS ON 
(Mean ± SD) 
p 
Repeats 8.6 ± 9.6 5.3 ± 5.7 0.10 
Brunet Index 7.32 ± 1.90 7.15 ± 1.66 0.55 
Honore 
Statistic 
481.8 ± 259.0 421.2 ± 295.1 0.66 
Type Token 0.86 ± 0.12 0.90 ± 0.08 0.17 
Table 3: Linguistic Features Extracted  
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4. Discussion: 
The purpose of our work was to explore and identify voice 
derived digital biomarkers, which could potentially help 
optimize the treatment of PD with DBS.  Our identification of 
significant differences amongst GeMAPS features provides 
promising results that acoustic voice changes are present and 
quantifiable. PD has been known to affect many of the motor 
mechanisms of voice, thus these findings are consistent with 
PD affecting acoustic properties of voice.  
Although none of the prosody features were statistically 
different for DBS ON vs OFF, negative correlations were 
present between prosodic features and motor symptom 
severity. Combined with the correlations that we generated 
between prosodic features, this is a promising sign that there 
could be a possible correlation to be further explored. 
Decreased total electrical energy delivered via DBS has been 
associated with improvement in speech prosody per [10]. 
Thus, the correlation we identified is consistent with prior 
findings, as prosodic features were found to improve with 
DBS OFF. 
Linguistic features explored also demonstrated no 
statistical difference for DBS ON vs OFF. Although the 
findings were insignificant, they provide results that could be 
further explored with an expanded data set. For the complex 
linguistic features, results seemed to conflict. DBS ON 
corresponded to a lower Brunet Index, meaning a richer 
lexical text as compared to the DBS OFF group. As for the 
Honore statistic, DBS ON was associated with a lower Honore 
Statistic, a less strong overall lexicon as compared to the DBS 
OFF group. These results demonstrate the differing linguistic 
features that could be associated with DBS ON or OFF, but 
further studies will need to be explored to demonstrate if the 
relationship is significant.  
4.1 Limitations: 
Our current study was limited by a few factors. The sample 
size of our study was only five individuals, with an age range 
of 34 years. This sample presents potential confounding due 
to varying age-related co-morbidities. Medication dosages 
were not controlled for, and all patients had differing LED’s 
at the time of data collection which could contribute to 
measured motor scores and voice characteristics. Lastly, the 
nature of individual variability on DBS settings for STN/GPI 
targeted DBS, would generate varying effects in each patient. 
The small sample size was not able to normalize any of these 
factors. 
5. Conclusion: 
This study provides preliminary evidence for voice 
biomarkers to act as an indicator for motor symptom severity 
amongst PD patients with DBS. Acoustic features provided 
significant differences associated with DBS in ON and OFF 
states, as well as prosodic features demonstrating a correlation 
with motor symptom severity. With the increased accessibility 
of voice recording devices and voice technology, voice data 
has potential utility in monitoring and optimizing DBS 
treatment without the need for patients to come into clinic. Our 
hope is to be able to gather data amongst a larger subset of 
DBS patients. This will allow us to utilize a data set where we 
can strengthen correspondence between motor symptom 
severity with voice features, and potentially apply towards 
voice operated closed-loop DBS. 
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